Gantenerumab for Alzheimer's Disease

"This medical trial has now closed for further enrolment. The initial posting date was November 18th 2020 and the latest update occured on September 23rd 2022. For those in search of alternative trials, 546 studies related to Alzheimer's disease are still open and 6 clinical studies that use Gantenerumab as a treatment are actively recruiting patients."

"Unfortunately, this research project is no longer taking on new recruits. Initially posted in November 2020 and last edited in September 2022, it has now filled its quota of participants. If you're looking for a clinical trial to join at present, there are 546 studies with Alzheimer’s as the primary focus and 6 additional trials that have Gantenerumab as their intervention."

"At present, 188 cities and 34 different nations are hosting 6 separate trials for Gantenerumab. The first of these studies was conducted in 2012 by Eisai Inc., which sought to demonstrate the efficacy of this drug through a Phase 2 & 3 clinical trial involving 490 participants. In the years since then, 10 additional trials have been launched."

"The safety profile of Gantenerumab was judged to have a risk rating of 2, as there is limited data regarding its efficacy but existing studies indicate it may be safe."

"Currently, there are 6 ongoing studies of Gantenerumab in the third phase. With most trials located in Dallas, Texas, this medication's clinical trails span 866 sites across America."

"This clinical trial adheres to an age range of 50-90 for its inclusion criteria, meaning that participants must be between these two ages to qualify."

"The current clinical trial is active in 8 different locations, such as Ocala, Gainesville and Willow Grove. To minimize travel time it is recommended to pick the closest site to your residence when enrolling."

"This particular medical trial is recruiting 192 participants, with an age range of 50 to 90 years old and a diagnosis of Alzheimer's disease. To be eligible for the study, they must also have adequate auditory/visual acuity to perform neuropsychological testing (with aids if necessary), confirmation of AD pathological process via amyloid PET scan, prodromal or mild symptomatology as determined by MMSE and CDR-GS scores, stable dosing regimen on symptomatic medications for 3 months prior to screening and until start of treatment period. Additionally, female participants must agree not to donate blood or participate in other research studies during this trial"